



Biotech Daily

Friday October 16, 2026

Daily news on ASX-listed biotechnology companies

- * ASX, BIOTECH UP: CURVEBEAM UP 14%; AMPLIA DOWN 20%
- * AUSBIOTECH GOLD COAST CONFERENCE NEXT WEEK
- * DR BOREHAM'S CRUCIBLE: IDENTIFAI GENETICS
- * MESOBLAST Q1 REVENUE UP 47% TO \$40m
- * AUSTCO UP-TO \$19.3m FOR RTM, CARETECH ACQUISITIONS
- * PYC OPTIONS EXERCISE RAISES \$1.2m
- * MAYNE, TEVA RESOLVE IMVEXXY VAGINAL INSERTS DISPUTE
- * FIREBRICK NASODINE APPROVED IN PHILIPPINES
- * AROA, MÖLNLYCKE CO-PROMOTE ENDOFORM IN US
- * DIMERIX: '100 PHASE III DMX-200 FSGS PATIENTS TREATED'
- * STARPHARMA REQUESTS 'STRATEGIC TRANSACTION' TRADING HALT
- * CERYVYN 21m BOARD OPTIONS AGM
- * VITRAFY 287k M-D BRENT OWENS RIGHTS AGM
- * IMMURON 'NON-ENDORSED' DIRECTOR PARAM LALLY AGM
- * IDT 5m CHAIR RIGHTS, 6m DIRECTOR OPTIONS AGM
- * RECCE EXTENDS AVENUE CAPITAL DRAW-DOWN TERMS
- * AMPLIA PLEADS 'SCHULTZ' TO ASX 21% PRICE DROP QUERY
- * ALGORAE, PETER MAC 3rd A.I. DRUG DISCOVERY VALIDATION
- * M&L, BLACK FAMILY TAKE 12.5% OF IDENTIFAI
- * DR ROBERT CANBY REPLACES EBR CMO DR SPENCER KUBO

MARKET REPORT

The Australian stock market was up 1.00 percent on Friday October 16, 2026, with the ASX200 up 87.0 points to 8,806.7 points.

Twenty of the Biotech Daily Top 40 companies were up, 12 fell, five traded unchanged and three were untraded. All four Big Caps were up.

Curvebeam was the best, up 0.3 cents or 14.3 percent to 2.4 cents, with 5.2 million shares traded.

Clarity and Pro Medicus climbed more than seven percent; Optiscan was up 6.45 percent; Artrya, Imugene and Neuren were up more than five percent; Actinogen, Avita, Dimerix, Proteomics and Telix improved four percent or more; Clinuvel, Emvision, Lumos, Orthocell and Polynovo were up more than three percent; CSL, Mesoblast, Nanosonics and Resmed rose more than two percent; Cochlear and Medical Developments were up more than one percent; with 4D Medical up by 0.25 percent.

Amplia led the falls on no news (see below), down 2.0 cents or 20 percent to 8.0 cents, with 16.4 million shares traded.

Syntara lost 13.6 percent; Resonance was down 9.9 percent; Aroa fell 5.6 percent; Cyclopharm, Micro-X, Prescient and Saluda were down more than four percent; Nova Eye shed 3.7 percent; with Alcidion, Imricor and Racura down by one percent or more.

AUSBIOTECH

Ausbiotech says its Ausbiotech, Ausbiotech Invest and Ausmedtech Gold Coast, Queensland conferences are next week from October 21 to 23, 2026.

In May, Ausbiotech said it would align its conferences into one “umbrella platform” called ‘Australia’s Biggest Week in Biotech’ (BD: May 29, Sep 10, 2026).

The organization said each conference would retain its own purpose and Ausmedtech would “remain the dedicated conference for Australia’s [medical technology] sector”.

Ausbiotech said that the Invest meeting would “continue as our standalone premier investment event with its own venue, registration pass, and dedicated program”.

Ausbiotech said its conference and Ausmedtech would be delivered as “a connected program experience, allowing delegates to move across sessions and engage more broadly across Australia’s life sciences ecosystem through a single registration pass”.

Ausbiotech said that Synthesis Bioventures managing-director Prof Andrew Wilks would deliver the Prof Nancy Millis Oration, sponsored by CSL, and described it as “one of the biotech industry’s most respected honors” (BD: Aug 20, 2025).

The industry organization said that Burns Service of Western Australia director and founder of Clinical Cell Culture (now Avita Medical) Prof Fiona Wood would deliver the Sanofi-sponsored Dr Irene Depaz Oration.

Ausbiotech said the program had more than 250 speakers in about 60 sessions, “bringing together ... leaders from across biotechnology, medical technology, health technology, investment, research, and government”, with 2,000 attendees expected.

Ausbiotech said the conferences would be held at the Gold Coast Convention and Exhibition Centre, with registration at: <https://biggestweekinbiotech.com/register/>.

DR BOREHAM'S CRUCIBLE: IDENTIFAI GENETICS

By TIM BOREHAM

ASX code: ID1

Share price: 40 cents

Shares on issue: 191,979,023

Market cap: \$76.8 million

Chief executive officer: Eyal Miller

Board: Yoseph Bornstein (chair), Kobi Caspi, Ata Gokyildirim, Lucy Robb Vujcic

Financials (year to December 31, 2025): revenue nil, net loss \$US1.7 million (\$US1.95 million deficit previously), cash used in operating activities \$US2.2 million (down 17%), cash of \$US669,000 (up 57%) (\$US1.00 = \$A1.43)

Major identifiable holders: Elegant Green Diamonds and Gold LLC 10.63%, M&L Nominees (Black family) 10.01%, Shizim VS Ltd (Messrs Bornstein and Caspi) 9.3%, EHV Israel LP/EHV Advanced 4.84%

On Tuesday, Tel Aviv's genetic screening innovator Identifai Genetics joined the ASX after raising \$10 million in a rare local biotech initial public offer (IPO).

Apart from 'what does Identifai do and why is it different', another question is: 'why is the Israeli company listed on the ASX?'

As it happens there have been plenty of precedents for such a migration across the technology sector generally, with varying degrees of success.

"The ASX is open minded about Israeli innovation, especially in the biotech sector," says Identifai CEO Eyal Miller. "The feedback we got from our partners in Australia is that the ASX is looking for breakthrough technologies."

In a recent concession, the ASX also welcomes non-revenue generating listees – so long as they are not far off doing so. Identifai aspires to satisfy that requirement, with aggressive plans to launch its flagship assay, the artificial intelligence (A.I.) enabled Windrose, in the US within months.

The key to such an expeditious approach is use of the US Food and Drug Administration's CLIA route (see below).

Mr Miller said the company expected to start commercialization in November.

"We are ready to go and as of the beginning of 2027 we'll start generating revenue".

Identifai yourself

Identifai Israel developed Windrose, a non-invasive pre-natal genetic testing platform combining whole-genome sequencing, advanced bio-informatics and artificial intelligence.

Founded in April 2021, Identifai Israel evolved from research carried out a decade ago at Tel Aviv University, by Dr Tom Rabinowitz. Dr Rabinowitz developed the algorithms underpinning the company, within the functional genomics lab of Prof Noam Shomron.

Identifai Israel licenced the technology from the university's transfer arm, Ramot.

"Since incorporation, the group has advanced from clinical proof-of-concept to an active US-based clinical development program," Identifai chair Yoseph Bornstein says.

Identifai Genetics was established in August 2025 to acquire Identifai Israel (a company incorporated under Israeli law).

Eyal Miller is a "seasoned" healthcare executive, with nearly three decades of industry experience. Identifai Israel's founder and chief scientific officer, Prof Noam Shomron, is an authority in genetics and genomics and was recently elected a Fellow of the US National Academy of Inventors.

A key figure in the Israeli bio-medical industry, Mr Bornstein also co-founded the Nasdaq-listed Microbot Medical. He founded life sciences holding group Shizim VS and has chaired multiple other companies.

Non-executive directors Ata Gokyildirim and Lucy Robb Vujcic are also on the board of the ASX-listed technology minnow Bluglass Limited.

About Windrose

Using a single maternal blood sample from about nine weeks of pregnancy, Windrose can identify a broader range of foetal genetic conditions than conventional non-invasive pre-natal testing (NIPT). The company focuses on monogenic disorders: those caused or controlled by a single gene.

Windrose provides a cell-free DNA (cfDNA) foetal risk assessment for more than 280 "clinically actionable" genes. That is, clinicians can take action to prevent the disorder.

The company says Windrose aims to address the inability of existing standard NIPT screening products to screen comprehensively for monogenic disorders.

Windrose identifies 296 troublesome genes that are "actionable" during – or shortly after - pregnancy. One example is Pompe disease, caused by a missing enzyme that can be injected during the pregnancy to ameliorate the disorder.

Conditions amenable to intervention during pregnancy include congenital adrenal hyperplasia, foetal anaemia, immune disorders and selected metabolic conditions.

“Time is of the essence,” Mr Miller says. “If those babies are not diagnosed on time ... that has a long-term impact and consequences on foetal morbidity or, in some cases, mortality.”

Current cfDNA screening is primarily recommended for common foetal aneuploidies (a cell with an abnormal number of chromosomes).

But a broader testing of inherited monogenic disease may involve maternal and reproductive-partner testing, or amnio-centesis (extracting a small sample of amniotic fluid from the sac around a foetus).

Currently, mothers routinely undergo a test for Down’s syndrome and to determine whether she is the carrier.

“The father also needs to be screened, but may be out of the picture,” Mr Miller said. “The only way to get clarity on whether the foetus is affected is to undergo an invasive procedure like amnio-centesis.”

One and done

With Windrose, the mother needs only provide one blood sample and her reproductive partner can be elsewhere. The Windrose test involves taking one sample at the hospital and sending it off to the CLIA -certified lab (see below).

“After that they undergo a genetic sequencing process, which obtains comprehensive information about the entire genome,” Mr Miller says.

The expectant mother or couple discuss risk assessment with a genetic counsellor or obstetrician. Even if the results are positive, there is sufficient time to reassess the risk and do an [invasive] confirmatory test before deciding on a treatment.

Mr Miller says the earlier the test is carried out the better, in terms of pregnancy management decisions.

“Most of the time the report will be negative so the couple can relax,” Mr Miller says.

Let’s be CLIA, it’s quicker

CLIA refers to Clinical Laboratory Improvements Amendment, and means that an FDA-certified laboratory can do the test.

“It’s much easier, faster, and cheaper,” Mr Miller says.

To ensure quality, only one laboratory nationally manages the assays.

The key is that the company doesn’t intend to approach the FDA for clearance.

Identifai's chosen laboratory in San Diego, California is run by Inocras and specializes in genomic testing.

Under the CLIA process a company may not have any contact with the FDA, but they need to be prepared for the agency to ask for validation down the track.

On trial

Via the CLIA route, Indentifai is "good to go" for a US launch, Mr Miller says.

But convincing conservative clinicians to change their practices requires more effort than putting out the 'open for business' shingle.

Covering 50 high-risk pregnancies, a validity study in the US and Israel reported "extremely encouraging" 100 percent overall accuracy against the diagnostic reference standard.

The company now plans a 600-patient US clinical validation, at six to eight well-known hospitals in 'real world' clinical conditions.

"We will do a head-to-head comparison by taking a saliva sample from the baby once born, which is the 'ground truth'," Mr Miller says.

"Or in cases where an invasive procedure has been done, we will use the amniotic test".

The study should take 12 months.

"You cannot shorten the process because if you're taking the blood sample at nine weeks of gestation, then you need to wait until the baby is born."

True: bio-science is yet to work out how to 'cook' a baby faster.

The company then plans a clinical utility study that appraises the financial benefits of using Windrose (such as reduced hospitalizations).

After that, Identifai hopes to snare a US commercial partner such as a key laboratory.

The US has about 5.5 million pregnancies annually.

Sizing the market

The World Health Organisation estimates that about six percent of babies worldwide are born with a congenital disorder.

Mr Miller notes that of the 140 million deliveries per annum, only about three percent involve serious congenital problems.

Various research houses estimate the size of the US NIPT/prenatal genetic testing market at \$US3.9 billion to \$US7.18 billion, growing at a compound annual 10-14 percent per annum.

The company says Windrose can scale from around 10 samples a day at launch, to more than 1,000 samples when fully operational

While the 296 genes screened by Identifai are the most common genetic problems, the company could cover hundreds more by tweaking the algorithm.

“It’s not about the number of genes, but the number that are actionable,” Mr Miller says.

Sizing up the competition

We must stress that Identifai will not be alone in the market.

The NIPT sector is competed by substantive companies including the Nasdaq-listed Natera and Billion To One, as well as Myriad Genetics, Labcorp, Quest Diagnostics, Fulgent Genetics, Roche, Revvity and Illumina.

“The competitive landscape is evolving rapidly,” Identifai says.

The large-scale providers, such as Labcorp and Quest, maintain dominant market share in standard chromosomal NIPT and carrier screening.

“A group of more innovation-driven companies (Natera, Billion To One, Myriad) are actively developing and launching products that extend prenatal genetic screening toward monogenic conditions,” Identifai says.

Identifai says that rather than signalling a saturated market, the presence of large well-capitalized players shows that comprehensive monogenic pre-natal screening is the “next significant frontier in pre-natal genetics”.

Finances and performance

The IPO involved issuing 50 million shares at 20 cents apiece, raising – tada! - \$10 million less costs.

The listing also included just over 10.15 million options, issued to the lead manager, exercisable at six US cents each, between 2033 and 2039.

Post-listing the company had pro-forma cash of just under \$10.7 million – enough to support the trial activity and keep the lights on generally.

Mr Miller estimates a US total addressable market (TAM) of \$US3 billion.

If most women do carrier screening – only 800,000 do at the moment – the TAM rises to \$US11-22 billion.

“There’s a lot for us to bite into,” Mr Miller says.

Did someone mention reimbursement?

Most insurers cover basic NIPT screening for up to \$US800. But add carrier (and expanded carrier) screening and the amount jumps to \$US4,400 to \$US4,700 per test.

“We can leverage on the current coding.”

For insurers the cost of not doing the testing can be enormous, given the suffering and difficulties an untreated baby could go on to suffer through their lifetime.

After listing, Identifai shares traded between 21.5 cents and 54 cents.

Dr Boreham’s diagnosis:

Given the extent of existing competition, Mr Miller says clinicians and facilities often ask why they should deal with a small Israeli company.

The proposed validation test should provide the requisite comfort.

Given the similar US reimbursement for Windrose to other tests, the clinicians and hospitals won’t be disadvantaged financially.

The company plans to focus on the US market initially - and sensibly - other markets with low, CLIA-like regulatory hurdles could follow.

This includes Europe where birth rates are plummeting, but folk haven’t quite given up on reproduction.

Mr Miller says that in providing the first and the only genome-wide approach platform, Identifai addresses an unmet market need with “true innovation”.

While revenue expectations are unclear, Mr Miller’s message to investors is “prepare to be amazed”.

He says: “We are going to create a lot of buzz in the US and once a commercial partner joins in that will create even more traction.”

Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Hopefully this is not a source of complete amazement to readers

MESOBLAST

Mesoblast says Ryoncil revenue for the three months to September 30, 2026 rose 47.4 percent to \$US28 million (\$A40 million), compared to the prior corresponding period. In 2024, Mesoblast said that the US Food and Drug Administration had approved Ryoncil, or remestemcel-L, for children with acute graft versus host disease (BD: Dec 19, 2024). Last year, the company said revenue from Ryoncil and Temcell sales in Japan for the three months to September 30, 2025 was \$US20.6 million (BD: Oct 20, 2025). Today, Mesoblast said that during September it “experienced the highest number of new patient starts per month, following the expected seasonality from summer recess-related treatment scheduling that occurs each July and August”. Mesoblast chief executive Prof Silviu Itescu said the company saw “strong year-on-year increase in net revenues and plan for continued growth by increasing penetration and adoption across the 54 on-boarded sites”. Today, the company said net operational cash expenditure fell 84.6 percent to \$US2.3 million and it had cash and cash equivalents of \$US99 million at September 30, 2026, compared to \$US145 million at September 30, 2025. Mesoblast was up five cents or 2.6 percent to \$1.99 with 17.6 million shares traded.

AUSTCO HEALTHCARE

Austco says it will acquire Brisbane’s RTM Hold Co Pty Ltd and Caretech Systems Pty Ltd for a total \$19.3 million, subject to the completion of both acquisitions. Austco said the RTM acquisition was subject to the completion of the Caretech acquisition, and vice versa, consent from customers, renewal of contracts and no material adverse change and were expected to be completed on December 1, 2026. The company said it would pay \$9.44 million up-front in cash to acquire RTM Hold Co Pty Ltd, the holding company of Real Time Monitoring Solutions and Real Time Monitoring Cloud, a provider of monitoring, reporting and systems-integration software. Austco said RMT’s vendor-agnostic platform had a library of more than 300 system interfaces, including an interface with its Tacera platform, and was deployed at more than 600 sites in Australia. The company said \$3.0 million of the up-front cash consideration was expected to be held in escrow pending renewal of a customer contract; and it would pay a performance-based, uncapped, cash earn-out expected to be \$5.82 million, taking the total to \$15.26 million. Austco said it would pay \$3.0 million up-front to acquire Caretech, a designer of nurse call products and systems for aged care and smaller hospital customers, as well as an expected about \$1.04 million in performance-based, uncapped, cash earn-outs, taking the total consideration to about \$4.04 million. The company said the acquisitions would be funded from existing cash reserves and a \$12.0 million loan with the Commonwealth Bank of Australia. Austco managing-director Clayton Astles said RTM was “Austco’s most significant acquisition to date and accelerates our shift towards software and recurring revenue ... [and Caretech] broadens our in-house nurse call portfolio with a lower-cost system”. Austco was up two cents or 8.7 percent to 25 cents with 1.355 million shares traded.

PYC THERAPEUTICS

PYC says it has raised \$1,190,000 through the exercise of 700,000 options at \$1.70 each, in set to expire on October 26, 2026. PYC was up six cents or 3.2 percent to \$1.91 with 3.2 million shares traded.

MAYNE PHARMA

Mayne Pharma says the Tel Aviv, Israel-based Teva Pharmaceuticals USA Inc has agreed to resolve the patent litigation relating to its Imvexxy estradiol vaginal inserts. In 2022, Mayne said it would pay Therapeutics MD \$US140 million (\$A225 million) for three women's health products and a portfolio of pre-natal vitamins (BD: Dec 5, 2022). At that time, the company said the products were Annovera for contraception, Imvexxy for painful intercourse and Bijuva for hot flushes, with the transaction to include "inventory and regulatory filings to support the operation and commercialization of the portfolio". Today, the company said the settlement resolved its ongoing patent litigation with Teva and provided an agreed pathway for potential entry of a Teva generic product on September 2, 2032, or earlier under certain circumstances, subject to court approval of the settlement terms.

Mayne said the settlement did "not include any financial payment or upfront monetary consideration between the parties".

The company said Imvexxy was a locally administered estradiol vaginal insert used in the treatment of moderate-to-severe dyspareunia, or painful intercourse, due to menopause, with net sales of \$US29.3 million (\$A42.33 million) in the year to June 30, 2026.

Mayne said following the settlement it had "no further ongoing Paragraph IV litigation matters for Imvexxy".

Last month, the company said Mumbai's Sun Pharmaceutical Industries agreed to resolve the US patent infringement litigation relating to Imvexxy (BD: Sep 30, 2026).

Today, Mayne chief executive officer Aaron Gray said following the settlement with Sun Pharma, the agreement with Teva resolved "all outstanding Paragraph IV litigation relating to Imvexxy".

"This provides a firm foundation for our longer-term planning for Imvexxy within our menopause portfolio and broader women's health business," Mr Gray said.

Mayne was up three cents or 1.2 percent to \$2.52.

FIREBRICK PHARMA

Firebrick says it has marketing approval from the Philippines Food and Drug Administration for its Nasodine nasal spray, subject to documentary requirements.

Last year, Firebrick said Singapore approved its Nasodine nasal spray and earlier this year, said it had approval in Indonesia (BD: Jun 13, 2024; Mar 27, 2026).

Today, the company said the approved packaging described the product as "nasal antiseptic designed to help reduce bacteria, viruses and fungi in the nose".

Firebrick said that uses included nasal infection, exposure to likely sources of respiratory infections and cold or flu-like symptoms to reduce the spread of infection.

The company said the approval was subject to Philippines licencing partner SV More Corporation meeting "standard post-approval documentary requirements".

Firebrick said the initial approval was valid until September 24, 2028 and thereafter subject to re-validation based on post-approval requirements compliance.

Firebrick executive chair Dr Peter Molloy said the approval was "a long-awaited and incredibly important milestone for Firebrick and our licencing partner and strategic investor, SV More".

"It is also our first approval of Nasodine within the [over-the-counter] drug category, which could be very useful in other jurisdictions," said Dr Molloy said.

"We will be working closely with SV More over the next few months to prepare for the product launch, which could occur as early as [April 2027]," said Dr Molloy said.

Firebrick was up 0.1 cents or 3.3 percent to 3.1 cents with 1.1 million shares traded.

AROA BIOSURGERY

Aroa says with Gothenburg, Sweden's Mölnlycke Healthcare it will co-promote its Endoform extra-cellular matrix products for acute and chronic wounds in the US. Aroa said Mölnlycke was a medical technology company specializing in products for wound care and surgical procedures "used daily by hospitals and health care providers and patients in over 100 countries".

The company said the agreement was effective from today and combined its product Endoform with Mölnlycke's "established market leading position and commercial reach". Aroa said the deal was expected to "expand access to Endoform in the US post-acute setting and support the product's continued growth".

The company said the agreement was solely for Endoform for post-acute settings in the US and it retained ownership of the technology and would continue to manufacture, distribute and supply the product.

Aroa said its 2026-'27 full-year revenue guidance remained unchanged at \$NZ115 million to \$NZ125 million (\$A94 million to \$A102 million).

The company did not disclose the commercial terms of the agreement.

Aroa managing-director Brian Ward said the agreement "allows us to concentrate our efforts on Aroa's strategic priorities, sustaining Myriad's growth and pursuing the significant opportunity for Symphony, while continuing to manufacture and supply Endoform".

Aroa fell three cents or 5.6 percent to 51 cents.

DIMERIX

Dimerix says 100 of 333 patients have completed the two-year treatment period in its phase III trial of DMX-200 in focal segmental glomerulosclerosis (FSGS).

Earlier this year, Dimerix said it began dosing the final adult patient in its phase III trial of DMX-200 for FSGS kidney disease, with the two-year treatment period expected to end in March 2028 (BD: Mar 10, 2026).

Today, the company said the completion of the first 100 patients was "an important execution milestone for the 'Action3' study and is a significant achievement given the rarity of FSGS and the recruitment challenges associated with rare diseases".

Dimerix said that as patients continued to complete the full double-blind treatment period "the remaining execution risk associated with long-duration treatment adherence, participant retention and successful trial execution reduces".

The company said 93 of the 100 patients had "elected to continue into the open-label extension study".

Dimerix said the open-label extension study allowed "the collection of important additional long-term safety and clinical outcome data ... [for] future regulatory activities".

Dimerix managing-director Dr Nina Webster said 100 patients completed was "not only an important clinical milestone, but also a significant operational achievement, for a global study of this size and duration".

Dimerix was up one cent or 4.8 percent to 22 cents.

STARPHARMA HOLDINGS

Starpharma has requested a trading halt "pending an announcement to the market regarding an update on a strategic transaction".

Trading will resume on October 20, 2026, or on an earlier announcement.

Starpharma last traded at 75 cents.

CERYVYN THERAPEUTICS (FORMERLY OPTHEA)

Ceryvyn says its annual general meeting will vote to issue 21,000,000 options to executive chair Dr Jeremy Levin and directors Lawrence Gozlan and Katherine Connell.

Last year, following two trials of OPT-302 for wet age-related macular degeneration not meeting their primary endpoints the then Opthea said it cut staff by 85 percent, its directors would step down and it paid a one-off settlement of \$US20 million (\$A31 million) to its DFA Investors and had \$20 million in cash (BD: Mar 24, 31, Jul 30, Aug 19, 2025). Today, the company said the meeting would vote to issue Dr Levin 9,000,000 options and Mr Gozlan and Ms Connell 6,000,000 options, each, exercisable at a 50 percent premium to the 10-day volume weighted average price of shares to the meeting date, within five years and vesting on 36 equal monthly instalments.

Ceryvyn said investors would vote to adopt the remuneration report, re-elect Mr Gozlan as a director, appoint the auditor, approve the employee awards plan, amend the constitution and approve the additional 10 percent placement capacity.

The meeting will be held at Bio101, Level 1, Suite 1, 117 Camberwell Road, Hawthorn East, Victoria on November 18, 2026 at 10am (AEDT).

Ceryvyn was up 0.05 cents or 4.8 percent to 1.1 cents with 1.65 million shares traded.

VITRAFY LIFE SCIENCES

Vitrafy says its annual general meeting will vote to issue 287,490 performance rights to managing-director Brent Owens.

Last week, Vitrafy said Mr Owens had relocated to the US and his salary was increased to \$US543,000 (\$A778,570) a year, including health insurance (BD: Oct 7, 2026).

Today, the company said the long-term incentive performance rights were valued at \$US802,500, and would vest on performance milestones.

Vitrafy said shareholders would vote to adopt the remuneration report, elect directors Dr Jeannette Joughin and Kate Munnings, ratify the prior issue of placement shares and approve the 10 percent placement facility.

The meeting will be held online and at Level 5, 111 Cecil Street, South Melbourne on November 17, 2026 at 1pm (AEDT).

Vitrafy fell one cent or 0.35 percent to \$2.86.

IMMURON

Immuron says its annual general meeting will vote to elect "non-board endorsed director candidate" Param Lally as a non-executive director.

Immuron said Mr Lally "nominated himself for election as a director in accordance with the company's constitution", was a shareholder and had been assessed as 'independent'.

The company said it recommended shareholders vote against the election of Mr Lally and that the chair intended to exercise all undirected proxies against the election.

According to a curriculum vitae attached to the meeting notice, Mr Lally had been chief financial officer of Challenger Services Group, a consultant for Saluda and had worked for Spotless Group, Broadspectrum Services and Worley Ltd.

The company said investors would vote to adopt the remuneration report, re-elect Dr Jeannette Joughin as a director, approve the increased placement capacity and renew the omnibus incentive plan.

The meeting will be held at Acclime Australia, Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria on November 18, 2026 at 2pm (AEDT).

Immuron fell 0.2 cents or 5.6 percent to 3.4 cents.

IDT AUSTRALIA

IDT says its annual general meeting will vote to issue 5,000,000 performance rights to chair Mark Simari and 6,000,000 options to directors Geoffrey Sam and Dr Jane Ryan. IDT said Mr Simari's performance rights would vest on revenue and earnings milestones in three annual tranches, would expire within five years from grant and were in addition to his \$324,360 base yearly pay.

The company said the meeting would vote to issue Mr Sam and Dr Ryan 3,000,000 options, each, vesting in three equal tranches subject to no conditions, with each tranche exercisable at 10 cents, 15 cents and 20 cents, respectively within three years.

IDT said the options were part of the directors' remuneration package in addition to Mr Sam's \$83,275 annual base salary and Dr Ryan's \$74,353 yearly fees.

The company said shareholders would vote on the remuneration report, to re-elect Mr Simari as a director, renew the employee share plan and approve the increased placement capacity.

The meeting will be held online and at Baker McKenzie, Level 19, 181 William Street, Melbourne on November 18, 2026 at 10am (AEDT).

IDT was unchanged at 3.8 cents.

RECCE PHARMACEUTICALS

Recce says it has extended the interest-only period and tranche-two draw-down period of its Avenue Capital loan by three months from September 30 to December 31, 2026.

Last year, Recce said it had a \$US20 million (\$A30 million) draw-down debt facility at 12.75 percent interest with New York's Avenue Capital Group; with an initial \$US7.5 million and further \$US5.0 million available by September 30, 2026 (BD: Jun 17, 2025).

Today, the company said the amended agreement included two subsequent interest-only extension options, potentially extending through to September 30, 2027.

Recce said access to the second tranche was contingent on clinical and funding milestones and it would issue 493,103 warrants, exercisable at 29 cents each by October 31, 2031 to Avenue Capital as consideration for the amendments.

Recce was up one cent or 3.6 percent to 29 cents.

AMPLIA THERAPEUTICS

Amplia has told the ASX that it is not aware of any information it has not announced which, if known, could explain the recent trading in its securities.

The ASX said the company's share price fell 21.0 percent from a closing price of 10 cents yesterday to a low of 7.9 percent today, and noted a "significant increase" in the volume of shares traded today.

Amplia fell two cents or 20 percent to eight cents with 16.4 million shares traded.

ALGORAE PHARMACEUTICALS (FORMERLY LIVING CELL TECHNOLOGIES)

Algorae says with Melbourne's Peter MacCallum Cancer Centre it will conduct a third validation program of predictions by its artificial intelligence (A.I.) operating system.

Last year, Algorae said with Peter MacCallum Cancer Centre it would study 24 A.I.-generated marijuana and drug combination candidates for cancer treatment; and in March, said that it would conduct a second program to validate predictions by its operating system (BD: May 8, 2025; Mar 30, 2026).

Algorae was up 0.1 cents or 12.5 percent to 0.9 cents with 2.8 million shares traded.

IDENTIFAI GENETICS

M&L Nominees Pty Ltd, Lynette Black and the Black Family say they have become substantial in Identifai with 23,920,036 shares, or 12.46 percent.

Perth's M&L, Ms Black and the Black Family said that on May 12, 2026 they bought 23,920,036 shares for \$2,000,000, or 8.4 cents a share.

On Tuesday, Identifai was up as much as 25 percent to 25 cents following its \$10 million initial public offer at 20 cents a share to develop its Windrose pre-natal genetic testing (BD: Oct 13, 2026).

Identifai fell five cents or 11.1 percent to 40 cents with 1.4 million shares traded.

EBR SYSTEMS

EBR says it has appointed Dr Robert Canby as its chief medical officer, to succeed seven-year chief medical officer Dr Spencer Kubo.

EBR said Dr Canby was "a board-certified cardiac electro-physiologist with extensive experience spanning clinical practice, physician education, cardiovascular research, and medical device innovation".

The company said Dr Canby worked at Austin's Texas Cardiac Arrhythmia Institute at St David's Medical Center and was head of the Texas Cardiac Arrhythmia Research Foundation.

EBR said Dr Canby would continue in his current clinical role at St David's and would work on its behalf "as his other duties permit".

The company said as chief medical officer Dr Canby would lead medical and clinical strategy, including evidence development, physician education and engagement, and collaboration with the company's research and development and commercial teams.

EBR was unchanged at 14 cents with 1.755 million shares traded.